ArticlePharmaceutics2022
Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity.Molecules (Basel, Switzerland) · 2026Article
- (5,6-Dimethyl-1,10-phenanthroline)(2-{[2-(di-phenyl-phosphan-yl)benzyl-idene]amino}-ethan-1-amine)-platinum(II) dinitrate methanol disolvate.Acta crystallographica. Section E, Crystallographic communications · 2025Article
- Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.International journal of molecular sciences · 2024Article
- Anticancer Effect of PtCancers · 2024Article
- Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.International journal of molecular sciences · 2024Article
- Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.Pharmaceutics · 2023Article
- Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs.Inorganic chemistry frontiers · 2023Article
- Platinum(IV) Derivatives of [Pt(1Journal of medicinal chemistry · 2023Article
- Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.Cancers · 2023Article
- Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.International journal of molecular sciences · 2023Article
- Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs.Molecules (Basel, Switzerland) · 2023Review
- Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.Pharmaceutics · 2022Article
- Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.Molecules (Basel, Switzerland) · 2022Article
- Potent Chlorambucil-Platinum(IV) Prodrugs.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Platinum(IV) prodrugs of the [Pt(P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.